SLC5A2 and Ventricular arrhythmia: Therefore, to investigate the hypothesis that SGLT2 inhibition reduces the incidence of ventricular arrhythmias, we undertook a post hoc analysis of DAPA-HF, examining serious adverse event (SAE) reports of ventricular arrhythmias, resuscitated cardiac arrest, and sudden death according to randomized assignment to dapagliflozin or placebo.